<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Circ Rep</journal-id><journal-id journal-id-type="iso-abbrev">Circ Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3977</journal-id><journal-id journal-id-type="pmc-domain">circreps</journal-id><journal-title-group><journal-title>Circulation Reports</journal-title></journal-title-group><issn pub-type="epub">2434-0790</issn><publisher><publisher-name>The Japanese Circulation Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12148353</article-id><article-id pub-id-type="pmcid-ver">PMC12148353.1</article-id><article-id pub-id-type="pmcaid">12148353</article-id><article-id pub-id-type="pmcaiid">12148353</article-id><article-id pub-id-type="pmid">40497118</article-id><article-id pub-id-type="doi">10.1253/circrep.CR-25-0026</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Ischemic Heart Disease</subject></subj-group></article-categories><title-group><article-title>An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention&#12288;&#8213; A Subgroup Analysis of the STOPDAPT-3 Trial &#8213;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names initials="K">Ko</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Natsuaki</surname><given-names initials="M">Masahiro</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watanabe</surname><given-names initials="H">Hirotoshi</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morimoto</surname><given-names initials="T">Takeshi</given-names></name><degrees>MD, MPH</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Obayashi</surname><given-names initials="Y">Yuki</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names initials="R">Ryusuke</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kimura</surname><given-names initials="T">Tomoya</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ando</surname><given-names initials="K">Kenji</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suwa</surname><given-names initials="S">Satoru</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Isawa</surname><given-names initials="T">Tsuyoshi</given-names></name><degrees>MD</degrees><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takenaka</surname><given-names initials="H">Hiroyuki</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names initials="T">Tetsuya</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yokomatsu</surname><given-names initials="T">Takafumi</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chinen</surname><given-names initials="T">Toshiya</given-names></name><degrees>MD</degrees><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doijiri</surname><given-names initials="T">Tatsuki</given-names></name><degrees>MD</degrees><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kozuma</surname><given-names initials="K">Ken</given-names></name><degrees>MD</degrees><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nishida</surname><given-names initials="Y">Yasunori</given-names></name><degrees>MD</degrees><xref rid="aff14" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names initials="K">Koji</given-names></name><degrees>MD</degrees><xref rid="aff15" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kitahara</surname><given-names initials="H">Hideki</given-names></name><degrees>MD</degrees><xref rid="aff16" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ishino</surname><given-names initials="M">Mitsunori</given-names></name><degrees>MD</degrees><xref rid="aff17" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ono</surname><given-names initials="K">Koh</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kimura</surname><given-names initials="T">Takeshi</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><collab>on behalf of the STOPDAPT-3 Investigators</collab></contrib><aff id="aff1">
<label>1)</label>
<institution>Department of Cardiology, Kokura Memorial Hospital</institution>
<addr-line>Kitakyushu</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff2">
<label>2)</label>
<institution>Department of Cardiovascular Medicine, Saga University</institution>
<addr-line>Saga</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff3">
<label>3)</label>
<institution>Department of Cardiology, Hirakata Kohsai Hospital</institution>
<addr-line>Osaka</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff4">
<label>4)</label>
<institution>Department of Data Science, Hyogo Medical University</institution>
<addr-line>Hyogo</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff5">
<label>5)</label>
<institution>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</institution>
<addr-line>Kyoto</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff6">
<label>6)</label>
<institution>Department of Cardiology, Japanese Red Cross Wakayama Medical Center</institution>
<addr-line>Wakayama</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff7">
<label>7)</label>
<institution>Department of Cardiology, Juntendo University Shizuoka Hospital</institution>
<addr-line>Shizuoka</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff8">
<label>8)</label>
<institution>Department of Cardiology, Sendai Kousei Hospital</institution>
<addr-line>Sendai</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff9">
<label>9)</label>
<institution>Department of Cardiology, Dokkyo Medical University Saitama Medical Center</institution>
<addr-line>Saitama</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff10">
<label>10)</label>
<institution>Department of Cardiology, Mitsubishi Kyoto Hospital</institution>
<addr-line>Kyoto</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff11">
<label>11)</label>
<institution>Department of Cardiology, Urasoe General Hospital</institution>
<addr-line>Okinawa</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff12">
<label>12)</label>
<institution>Department of Cardiology, Yamato Seiwa Hospital</institution>
<addr-line>Kanagawa</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff13">
<label>13)</label>
<institution>Division of Cardiology, Teikyo University Hospital</institution>
<addr-line>Tokyo</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff14">
<label>14)</label>
<institution>Department of Cardiovascular Medicine, Kouseikai Takai Hospital</institution>
<addr-line>Nara</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff15">
<label>15)</label>
<institution>Department of Cardiovascular Medicine, Tokushima University Hospital</institution>
<addr-line>Tokushima</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff16">
<label>16)</label>
<institution>Department of Cardiovascular Medicine, Chiba University Hospital</institution>
<addr-line>Chiba</addr-line>
<country country="JP">Japan</country>
</aff><aff id="aff17">
<label>17)</label>
<institution>Department of Cardiology, Higashiyamato Hospital</institution>
<addr-line>Tokyo</addr-line>
<country country="JP">Japan</country>
</aff><author-comment><p>Clinical trial registration: ShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04609111">NCT04609111</ext-link>. K.O. is a member of Circulation Reports&#8217; Editorial Team.</p></author-comment></contrib-group><author-notes><label>Mailing address</label><fn fn-type="edited-by"><p>Takeshi Kimura, MD</p></fn><corresp id="corr1"><institution>Department of Cardiology, Hirakata Kohsai Hospital</institution><addr-line>1-2-1 Fujisakahigashimachi, Hirakata, Osaka 573-0153</addr-line><country country="JP">Japan</country><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="taketaka@kuhp.kyoto-u.ac.jp">taketaka@kuhp.kyoto-u.ac.jp</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>10</day><month>6</month><year>2025</year></pub-date><volume>7</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">490231</issue-id><fpage>451</fpage><lpage>462</lpage><history><date date-type="received"><day>11</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-11 20:25:16.437"><day>11</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, THE JAPANESE CIRCULATION SOCIETY</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Japanese Circulation Society</copyright-holder><copyright-holder xml:lang="ja">&#19968;&#33324;&#31038;&#22243;&#27861;&#20154; &#26085;&#26412;&#24490;&#29872;&#22120;&#23398;&#20250;</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="circrep-7-451.pdf"/><abstract abstract-type="section"><sec><title>Background</title><p>No previous studies have evaluated the effect of an aspirin-free strategy for patients undergoing staged percutaneous coronary intervention (PCI).</p></sec><sec><title>Methods and Results</title><p>We conducted a post hoc subgroup analysis in patients undergoing staged PCI within 1 month in STOPDAPT-3 (n=6,002), which randomly compared prasugrel monotherapy with dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome or high bleeding risk. The co-primary endpoints were major bleeding (Bleeding Academic Research Consortium 3 or 5) and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) at 1 month. There were 814 patients undergoing staged PCI within 1 month (no-aspirin group, n=401; DAPT group, n=413). The median interval from randomization to the first staged PCI was 8 (interquartile range 5&#8211;13) days. More than 90% of the patients received assigned antiplatelet agents at all staged PCI procedures. The effect of no-aspirin relative to DAPT was not different for the co-primary bleeding (3.74% vs. 1.94%; HR 1.94; 95% CI 0.82&#8211;4.57) and cardiovascular (3.49% vs. 2.42%; HR 1.44; 95% CI 0.64&#8211;3.25) endpoints. The no-aspirin group compared with the DAPT group had a numerically higher incidence of the co-primary cardiovascular endpoint, which occurred after the first staged PCI procedure (2.49% vs. 1.21%; HR 2.07; 95% CI 0.71&#8211;6.05).</p></sec><sec><title>Conclusions</title><p>An aspirin-free prasugrel monotherapy relative to DAPT had numerically higher risks of cardiovascular and major bleeding events in patients undergoing staged PCI at 1 month.</p></sec></abstract><kwd-group kwd-group-type="author"><label>Key Words:</label><kwd>Antiplatelet therapy</kwd><kwd>Coronary stent</kwd><kwd>Percutaneous coronary intervention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Patients undergoing percutaneous coronary intervention (PCI) for multiple lesions sometimes require multiple procedures to complete revascularization, which is known as a &#8216;staged PCI procedure&#8217;.<xref rid="B1" ref-type="bibr"><sup>1</sup></xref><sup>&#8211;</sup><xref rid="B4" ref-type="bibr"><sup>4</sup></xref> Completing PCI for all target lesions in a single session would be ideal to avoid multiple procedures, reduce cost, and treat vulnerable lesions immediately. However, there are some clinical and non-clinical reasons to perform staged PCI procedures in real-world practice.<xref rid="B1" ref-type="bibr"><sup>1</sup></xref> Dual antiplatelet therapy (DAPT) with aspirin and a P2Y<sub>12</sub>
inhibitor is the standard antiplatelet regimen during the periprocedural period in patients undergoing PCI.<xref rid="B5" ref-type="bibr"><sup>5</sup></xref><sup>&#8211;</sup><xref rid="B7" ref-type="bibr"><sup>7</sup></xref> In contrast, several single-arm studies suggest the safety and feasibility of an aspirin-free P2Y<sub>12</sub>
inhibitor monotherapy immediately after PCI.<xref rid="B8" ref-type="bibr"><sup>8</sup></xref><sup>&#8211;</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref> However, patients requiring staged PCI were not enrolled in these studies. Recently, the STOPDAPT-3 (ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3) trial demonstrated that an aspirin-free strategy compared with the DAPT strategy failed to reduce major bleeding at 1 month after PCI, with a signal suggesting increased coronary events such as definite or probable subacute stent thrombosis and any unplanned coronary revascularization in patients with acute coronary syndrome or high bleeding risk.<xref rid="B11" ref-type="bibr"><sup>11</sup></xref> Because patients undergoing staged PCI were exposed to the risk of periprocedural thrombotic complications by multiple procedures, there is concern regarding the adoption of an aspirin-free strategy for patients undergoing staged PCI.<xref rid="B4" ref-type="bibr"><sup>4</sup></xref> In contrast, an aspirin-free strategy might be an attractive regimen in patients undergoing staged PCI because of multiple periprocedural bleeding risk.<xref rid="B4" ref-type="bibr"><sup>4</sup></xref> In the present study, we aimed to evaluate the safety and efficacy of an aspirin-free strategy for patients undergoing staged PCI using the data from STOPDAPT-3.</p><sec><title>Methods</title><sec><title>Study Design and Population</title><p>STOPDAPT-3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04609111">NCT04609111</ext-link>) was a physician-initiated, prospective, multicenter, open-label, adjudicator blinded randomized clinical trial where we compared the bleeding and cardiovascular outcomes between an experimental group of 1-month prasugrel monotherapy without aspirin and a control group of 1-month DAPT with aspirin and prasugrel in patients planned for PCI using cobalt-chromium everolimus-eluting stent (CoCr-EES: Xience<sup>TM</sup>
series, ABBOTT Vascular) implantation. The detailed study protocol and main results are reported elsewhere.<xref rid="B11" ref-type="bibr"><sup>11</sup></xref> The study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. In brief, a total of 6,002 patients with acute coronary syndrome regardless of Academic Research Consortium high bleeding risk (ARC-HBR) or non-acute coronary syndrome with high bleeding risk were enrolled between January 2021 to April 2023 from 72 centers in Japan, and were randomly allocated immediately before PCI in a 1-to-1 ratio to either prasugrel monotherapy without aspirin (no-aspirin group) or to 1-month DAPT with aspirin and prasugrel (DAPT group).</p><p>After randomization, a loading dose of prasugrel 20 mg was administered in both groups. A loading dose of aspirin 162&#8211;200 mg was also administered in aspirin-na&#239;ve patients in the DAPT group. Prasugrel 3.75 mg/day in the no-aspirin group, and aspirin 81&#8211;100 mg/day and prasugrel 3.75 mg/day in the DAPT group were continued up to 1 month after PCI. At the 1-month (30&#8211;59 days) visit, prasugrel was switched to clopidogrel and was continued up to 1 year in the no-aspirin group, while prasugrel was discontinued and aspirin monotherapy was continued up to 1 year in the DAPT group. The ethical committees in all the participating centers approved the study protocol, and informed consent was obtained from all patients.</p><p>The present study was a post hoc subgroup analysis in patients who underwent staged PCI within 1 month in STOPDAPT-3. Among 6,002 patients who underwent randomization, we excluded 5 patients who did not undergo the index PCI due to the absence of suitable coronary lesions, 1 patient who had been enrolled in another clinical trial, 30 patients who withdrew consent, and 5,152 patients who did not undergo the staged PCI within 1 month. Therefore, the population in the present study consisted of 814 patients who underwent the first index PCI and staged PCI within 1 month (<xref rid="F1" ref-type="fig"><bold>Figure&#8197;1</bold></xref>). Staged PCI was defined as PCI procedures planned at the time of the first index PCI.<xref rid="B1" ref-type="bibr"><sup>1</sup></xref> Staged PCI was recommended to be performed within 3 months after the randomization, although the actual execution, timing, and number of staged PCI were left to the discretion of each attending physician. Recommended antiplatelet therapy at the staged PCI before the primary analysis of 1 month was continuing each assigned regimen; only prasugrel 3.75 mg/day should be continued without loading in the no-aspirin group, while aspirin 81&#8211;100 mg/day and prasugrel 3.75 mg/day should be continued without loading in the DAPT group. In the no-aspirin group, aspirin should not be administrated even at the time of staged PCI. Planned staged PCI procedures were not regarded as follow-up events, but included in the index PCI procedure. In contrast, any unplanned PCI, even if it was performed before planned staged PCI, was regarded as a follow-up event.
<fig position="float" id="F1" orientation="portrait"><label>Figure&#8197;1.</label><caption><p>Study flow chart. ACS, acute coronary syndrome; DAPT, dual antiplatelet therapy; HBR, high bleeding risk; PCI, percutaneous coronary intervention.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="circrep-7-451-g001.jpg"/></fig>
</p></sec><sec><title>Endpoints</title><p>The co-primary bleeding endpoint was major bleeding defined as the Bleeding Academic Research Consortium (BARC) type 3 or 5, and the co-primary cardiovascular endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke.<xref rid="B12" ref-type="bibr"><sup>12</sup></xref> The major secondary endpoint was a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, ischemic stroke, or major bleeding (BARC 3 or 5), which represented net adverse clinical outcomes for cardiovascular and bleeding events. Myocardial infarction and stent thrombosis were defined by the Academic Research Consortium criteria.<xref rid="B13" ref-type="bibr"><sup>13</sup></xref> The definitions of other secondary endpoints are described in the <xref rid="S1" ref-type="supplementary-material"><bold>Supplementary File</bold></xref>. The independent clinical event committee adjudicated all the clinical events in a blinded fashion to the assigned group.</p></sec><sec><title>Statistical Analysis</title><p>Categorical variables are presented as number and percentage and were compared using the chi-square test. Continuous variables were expressed as mean&#177;standard deviation or median with interquartile range, and were compared using the Student t-test or Wilcoxon rank-sum test depending on their distributions. The cumulative incidences of the endpoints were estimated using the Kaplan-Meier method. The effect of the no-aspirin group relative to the DAPT group for the endpoints were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs) using the Cox proportional hazard model. We also evaluated the co-primary bleeding and cardiovascular endpoints that occurred after the first staged PCI procedure. In addition, the sensitivity analyses were performed after excluding patients who did not receive assigned antiplatelet agents at any staged PCI. Furthermore, we conducted the subgroup analysis stratified by acute or non-acute coronary syndrome. All reported P values were 2-sided. P values &lt;0.05 were considered statistically significant. All analysis was performed with R version 4.2.3 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec><title>Results</title><sec><title>Baseline Characteristics</title><p>There were 401 patients in the no-aspirin group and 413 patients in the DAPT group (<xref rid="F1" ref-type="fig"><bold>Figure&#8197;1</bold></xref>). In the total study population, the mean age was 71.0 years, 78.6% of the patients were men, and 83.7% of the patients presented as acute coronary syndrome (<xref rid="T1" ref-type="table"><bold>Table&#8197;1</bold></xref>). The mean estimated glomerular filtration rate (eGFR) was 58.3 mL/min/1.73 m<sup>2</sup>, and the prevalence of moderate (eGFR 30&#8211;59 mL/min/1.73 m<sup>2</sup>) and severe (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>
or hemodialysis) chronic kidney disease was 40.5% and 10.0%, respectively. Multivessel PCI targets were presented in 92.6% of patients with a mean number of target lesions of 2.4, and 10.0% of patients had a chronic total occlusion target. Intravascular imaging was used in 93.1% of patients. Baseline characteristics were well balanced between the no-aspirin and DAPT groups, except for the higher prescription rate of proton-pump inhibitors in the DAPT group compared with the no-aspirin group.
<table-wrap position="float" id="T1" orientation="portrait"><label>Table&#8197;1.</label><caption><p>Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#160;</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Study population <break/>(n=814)</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No-aspirin group <break/>(n=401)</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT group <break/>(n=413)</th></tr></thead><tbody><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Patient demographics</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Age (years)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71.0&#177;11.3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71.0&#177;10.9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">70.9&#177;11.8</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#8805;75</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">332 (40.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">170 (42.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">162 (39.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Sex, male</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">640 (78.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">324 (80.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">316 (76.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Body mass index (kg/m<sup>2</sup>)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24.2&#177;3.9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24.0&#177;3.7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24.3&#177;4.1</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Clinical presentation</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Acute coronary syndrome</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">681 (83.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">333 (83.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">348 (84.3)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;STEMI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">399 (49.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">184 (45.9)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">215 (52.1)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Door to wire crossing time within 24 h of onset (min)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">45 [34&#8211;55]</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">46 [32&#8211;55]</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">45 [36&#8211;54]</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;NSTEMI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">187 (23.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">102 (25.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">85 (20.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Unstable angina</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">95 (11.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">47 (11.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">48 (11.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Cardiac arrest or ventricular fibrillation</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7 (0.9)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Cardiogenic shock</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">35 (4.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15 (3.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">20 (4.8)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Current heart failure</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">168 (20.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81 (20.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">87 (21.1)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Past history and comorbidities</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Prior PCI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">91 (11.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">47 (11.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">44 (10.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Prior coronary artery bypass grafting</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (0.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Prior myocardial infarction</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">42 (5.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24 (6.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (4.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Prior stroke</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">67 (8.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">27 (6.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">40 (9.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Prior heart failure</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">43 (5.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">20 (5.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">23 (5.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Atrial fibrillation</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">51 (6.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">27 (6.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24 (5.8)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Diabetes</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">346 (42.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">171 (42.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">175 (42.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Current smoker</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">226 (27.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">108 (26.9)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">118 (28.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Left ventricular ejection fraction (%)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">53.3&#177;10.8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">53.1&#177;10.4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">53.5&#177;11.3</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Estimated glomerular filtration rate (mL/min/1.73 m<sup>2</sup>)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">58.3&#177;22.0</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">57.6&#177;21.8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">59.1&#177;22.1</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Moderate chronic kidney disease</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">330 (40.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">174 (43.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">156 (37.8)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Severe chronic kidney disease</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81 (10.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">38 (9.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">43 (10.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Hemodialysis</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">36 (4.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (4.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (4.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Cancer history</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">72 (8.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">28 (7.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">44 (10.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;ARC-HBR</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">389 (47.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">195 (48.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">194 (47.0)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Procedural characteristics</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Radial approach</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">697 (85.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">346 (86.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">351 (85.0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Radial approach only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">641 (78.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">320 (79.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">321 (77.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Femoral approach</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">153 (18.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71 (17.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">82 (19.9)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Brachial approach</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19 (2.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10 (2.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;No. target lesions</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.4&#177;0.7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.4&#177;0.7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.4&#177;0.7</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Target of &#8805;2 vessels</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">754 (92.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">374 (93.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">380 (92.0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Target of chronic total occlusion</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81 (10.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">36 (9.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">45 (10.9)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Target of bifurcation lesion</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">338 (41.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">174 (43.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">164 (39.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Bifurcation 2 stents</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (2.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Target of left main coronary artery</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">86 (10.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">49 (12.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">37 (9.0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;No. implanted stents</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.6&#177;1.1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.7&#177;1.1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.6&#177;1.0</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Total stent length (mm)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71.0&#177;34.9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71.1&#177;35.6</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">70.8&#177;34.4</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Use of intravascular imaging</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">758 (93.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">376 (93.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">382 (92.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Intubation</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19 (2.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10 (2.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Hemodynamic support device use</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80 (9.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">35 (8.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">45 (10.9)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;IABP use</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">76 (9.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">33 (8.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">43 (10.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;ECMO use</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Impella use</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (0.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Continuous hemofiltration use</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15 (1.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6 (1.5)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Medication within 7 days before assignment</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Antiplatelet agents</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">216 (26.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">115 (28.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">101 (24.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">150 (18.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">77 (19.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">73 (17.7)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;P2Y<sub>12</sub> inhibitors only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">39 (4.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">21 (5.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (4.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">27 (3.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">17 (4.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10 (2.4)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Aspirin/prasugrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">11 (1.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6 (1.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Aspirin/clopidogrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">14 (1.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 (2.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Anticoagulants</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">44 (5.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">22 (5.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">22 (5.3)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Warfarin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6 (13.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (13.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (13.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Direct oral anticoagulants</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">38 (86.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19 (86.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19 (86.4)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Medication at index PCI</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Loading of prasugrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">812 (99.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">400 (99.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">412 (99.8)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Loading of aspirin in the DAPT group</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">356 (86.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">356 (86.4)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Medication after the index PCI or at discharge</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#946;-blockers</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">546 (70.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">269 (70.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">277 (69.6)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Statins</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">736 (94.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">357 (93.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">379 (95.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;High-intensity statin therapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">446 (57.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">218 (57.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">228 (57.3)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Proton-pump inhibitors</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">707 (90.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">334 (87.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">373 (93.7)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Categorical variables are presented as n (%). Continuous variables are presented as mean&#177;SD, or median [interquartile range]. Moderate and severe chronic kidney disease are defined using the criteria in the ARC-HBR (moderate: estimated glomerular filtration rate 30&#8211;59 mL/min/1.73 m<sup>2</sup>; severe: estimated glomerular filtration rate &lt;30 mL/min/1.73 m<sup>2</sup> or hemodialysis). Values are missing for left ventricular ejection fraction in 40 patients, estimated glomerular filtration rate in 2 patients, and total stent length in 1 patient. Number of target lesions and total stent length are based on the first index PCI, as well as the staged PCI within 1 month. High-intensity statin therapy is defined as use of the maximum approved dose of strong statins in Japan (e.g., rosuvastatin 10 mg, atorvastatin 20 mg, or pitavastatin 4 mg). ARC-HBR, Academic Research Consortium for high bleeding risk; DAPT, dual-antiplatelet therapy; ECMO, extracorporeal membrane oxygenation; HBR, high bleeding risk; IABP, intra-aortic balloon pumping; NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.</p></fn></table-wrap-foot></table-wrap>
</p><p>In the study population, 92.8% of the patients had 1 staged PCI procedure, 6.9% of the patients had 2 staged PCI procedures, and 0.4% of the patients had 3 staged PCI procedures (<xref rid="T2" ref-type="table"><bold>Table&#8197;2</bold></xref>). The median interval from randomization to the first staged PCI was 8 (interquartile range 5&#8211;13) days. The status of antiplatelet agents at the staged PCI is presented in <xref rid="T2" ref-type="table"><bold>Table&#8197;2</bold></xref>. The prevalence of patients receiving assigned antiplatelet agents at all staged PCI procedures was 92.8% in the no-aspirin group and 99.3% in the DAPT group. During the study period of 1 month, the majority of the study patients received the assigned antiplatelet agents (<xref rid="S1" ref-type="supplementary-material"><bold>Supplementary Figure&#8197;1</bold></xref>).
<table-wrap position="float" id="T2" orientation="portrait"><label>Table&#8197;2.</label><caption><p>Details of the Staged PCI</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#160;</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Staged PCI <break/>(n=814)</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No-aspirin group <break/>(n=401)</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT group <break/>(n=413)</th></tr></thead><tbody><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>No. staged PCI</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">755 (92.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">373 (93.0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">382 (92.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">56 (6.9)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">27 (6.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">29 (7.0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Days from randomization to the first staged PCI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8 [5&#8211;13]</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9 [5&#8211;14]</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8 [5&#8211;12]</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Antiplatelet agents at the first staged PCI</bold></td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=814</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=401</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=413</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Aspirin only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;P2Y<sub>12</sub> inhibitors only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">375 (46.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">375 (93.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Prasugrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">372 (45.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">372 (92.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Clopidogrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">435 (53.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (6.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">411 (99.5)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/prasugrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">431 (52.9)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">22 (5.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">410 (99.3)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/clopidogrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (0.5)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;No antiplatelet therapy<sup>&#8224;</sup></td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Antiplatelet agents at the second staged PCI</bold></td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=59</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=28</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=31</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Aspirin only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;P2Y<sub>12</sub> inhibitors only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (42.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (89.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Prasugrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (42.4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (89.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Clopidogrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">34 (57.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (10.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">31 (100)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/prasugrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">34 (57.6)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (10.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">31 (100)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/clopidogrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;No antiplatelet therapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Antiplatelet agents at the third staged PCI</bold></td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">n=2</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Aspirin only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;P2Y<sub>12</sub> inhibitors only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (33.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (100)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Prasugrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (33.3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (100)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Clopidogrel only</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (66.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (100)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/prasugrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (66.7)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (100)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Aspirin/clopidogrel</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;No antiplatelet therapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Patients receiving assigned antiplatelet agents at all staged PCI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">782 (96.1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">372 (92.8)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">410 (99.3)</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>Categorical variables are presented as n (%). Continuous variables are presented as median [interquartile range]. <sup>&#8224;</sup>One patient (no-aspirin group) did not receive any antiplatelet therapy at the first staged PCI. The patient could not complete the first index PCI procedure due to access-site bleeding and discontinued prasugrel. After healing of the access-site bleeding, staged PCI was performed without any antiplatelet therapy, and prasugrel monotherapy was re-initiated from the next day of the staged PCI. PCI, percutaneous coronary intervention.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Clinical Outcomes</title><p>The co-primary bleeding endpoint occurred in 15 (3.74%) patients in the no-aspirin group and 8 (1.94%) patients in the DAPT group at 1 month (HR 1.94; 95% CI 0.82&#8211;4.57; P=0.13) (<xref rid="F2" ref-type="fig"><bold>Figure&#8197;2A</bold></xref>). The co-primary bleeding endpoint after the first staged PCI occurred in 5 (1.25%) patients in the no-aspirin group and 3 (0.73%) patients in the DAPT group (HR 1.71; 95% CI 0.41&#8211;7.18; <xref rid="T3" ref-type="table"><bold>Table&#8197;3</bold></xref>). The details of the co-primary bleeding endpoint are shown in <xref rid="T4" ref-type="table"><bold>Table&#8197;4A</bold></xref>. Among 15 patients who had a co-primary bleeding endpoint in the no-aspirin group, 4 patients (numbers 3, 7, 11, and 14 in <xref rid="T4" ref-type="table"><bold>Table&#8197;4A</bold></xref>) were considered to have a procedural complication (e.g., access-site bleeding, ischemic stroke with hemorrhagic conversion, or cardiac tamponade) due to the staged PCI. Among 8 patients who had a co-primary bleeding endpoint in the DAPT group, 1 patient (number 20 in <xref rid="T4" ref-type="table"><bold>Table&#8197;4A</bold></xref>) was considered to have a procedural complication (e.g., access-site bleeding) due to the staged PCI.
<fig position="float" id="F2" orientation="portrait"><label>Figure&#8197;2.</label><caption><p>Kaplan-Meier curves for the co-primary endpoints. (<bold>A</bold>) Co-primary bleeding endpoint, and (<bold>B</bold>) co-primary cardiovascular endpoint. CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="circrep-7-451-g001.jpg"/></fig>
<table-wrap position="float" id="T3" orientation="portrait"><label>Table&#8197;3.</label><caption><p>Clinical Outcomes at 1 Month</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" style="white-space:nowrap;" colspan="1">Outcome</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No-aspirin group <break/>(n=401)</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT group <break/>(n=413)</th><th rowspan="2" align="center" style="white-space:nowrap;" colspan="1">Hazard ratio <break/>(95% CI)</th></tr><tr><th colspan="2" align="center" style="white-space:nowrap;" rowspan="1">No. patients with event <break/>(cumulative incidence %)</th></tr></thead><tbody><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Co-primary bleeding endpoint</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 3 or 5 bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15 (3.74)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8 (1.94)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.94 (0.82&#8211;4.57)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;After the first staged PCI procedure</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.71 (0.41&#8211;7.18)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Co-primary cardiovascular endpoint</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;A composite of cardiovascular death, MI, definite stent thrombosis, <break/>or ischemic stroke</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">14 (3.49)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10 (2.42)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.44 (0.64&#8211;3.25)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;After the first staged PCI procedure</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10 (2.49)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.21)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.07 (0.71&#8211;6.05)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Major secondary endpoint</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;A composite of cardiovascular death, MI, definite stent thrombosis, <break/>ischemic stroke, or BARC 3 or 5 bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">25 (6.23)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18 (4.36)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.44 (0.78&#8211;2.63)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Secondary endpoint</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Death</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.24)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3.09 (0.32&#8211;29.69)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Cardiovascular causes</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.24)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3.09 (0.32&#8211;29.69)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Sudden death</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Non-cardiovascular causes</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Stroke</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.37 (0.31&#8211;6.12)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Ischemic</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.03 (0.21&#8211;5.09)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Hemorrhagic</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;MI</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8 (2.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.21)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.65 (0.54&#8211;5.05)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Spontaneous</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4.13 (0.46&#8211;36.91)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Procedural</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.01)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (0.97)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.03 (0.26&#8211;4.13)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Definite or probable stent thrombosis</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (0.97)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.09&#8211;2.81)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Acute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.48)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.68)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Subacute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.49)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.66)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Definite</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (0.97)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.09&#8211;2.81)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Acute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.48)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.68)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Subacute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.49)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.66)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Probable</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Acute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Subacute</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Any coronary revascularization (unplanned)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7 (1.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7 (1.70)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.03 (0.36&#8211;2.93)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Target lesion (unplanned)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6 (1.46)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.13&#8211;2.05)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Non-target lesion (unplanned)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.49)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.06 (0.38&#8211;11.26)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Bleeding</bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 2, 3 or 5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">30 (7.48)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19 (4.61)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.65 (0.93&#8211;2.93)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">14 (3.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8 (1.94)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.81 (0.76&#8211;4.31)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;BARC 2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15 (3.74)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">12 (2.91)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.30 (0.61&#8211;2.78)</td></tr><tr><td colspan="4" align="left" style="white-space:nowrap;" rowspan="1"><bold>Location of bleeding: BARC 3 or 5<sup>&#8224;</sup></bold></td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Intracranial bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Gastrointestinal bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.50)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.68 (0.11&#8211;4.10)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Access-site bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7 (1.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2.40 (0.62&#8211;9.29)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;PCI access</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4 (1.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.73)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1.37 (0.31&#8211;6.13)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Radial access</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.48)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.68)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;&#12288;Non-radial access</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.24)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3.09 (0.32&#8211;29.71)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;&#12288;Non-PCI access</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3 (0.75)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Cardiac tamponade</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;PCI procedure-related bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1 (0.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2 (0.48)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0.51 (0.05&#8211;5.67)</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Surgery procedure-related bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Retroperitoneum bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Pulmonary bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Genitourinary bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Intraocular bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">&#12288;Other bleeding</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5 (1.25)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">0 (0.00)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p><sup>&#8224;</sup>Some patients had bleeding in multiple locations. Non-PCI access indicated arterial and venous access other than the access for PCI. Cumulative incidences of the endpoints were estimated using the Kaplan-Meier method. The hazard ratio and 95% CI for the no-aspirin group relative to the DAPT group were estimated with the Cox proportional hazard model. Acute stent thrombosis was defined as that occurring within 24 h of PCI, and subacute stent thrombosis was defined as that occurring beyond 24 h and up to 30 days after PCI. BARC, Bleeding Academic Research Consortium; CI, confidence interval; DAPT, dual antiplatelet therapy; MI, myocardial infarction; PCI, percutaneous coronary intervention.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="float" id="T4" orientation="portrait"><label>Table&#8197;4.</label><caption><p>Details of the Events Adjudicated as the Co-Primary Bleeding and Cardiovascular Endpoints, (A) Co-Primary Bleeding Endpoint of BARC 3 or 5 Bleeding, (B) Co-Primary Cardiovascular Endpoint of a Composite of Cardiovascular Death, MI, Definite Stent Thrombosis, or Ischemic Stroke</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">(A) <break/>No.</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Assigned <break/>group</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Age <break/>(years), <break/>sex</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Presentation</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Target <break/>lesion in the <break/>index PCI</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Target lesion <break/>in the <break/>first staged PCI</th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Antiplatelet <break/>agents at the <break/>first staged PCI</th><th colspan="3" align="center" style="white-space:nowrap;" rowspan="1">Details of the event</th></tr></thead><tbody><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LCX at <break/>Day 16</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">ECMO access-site bleeding at Day 3 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">66, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA at <break/>Day 5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Unknown-site bleeding at Day 1 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Ischemic stroke with hemorrhagic conversion due to <break/>first staged PCI at Day 9 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 19</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI procedure-related bleeding due to index PCI at Day <break/>5 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">74, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 23</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Gastrointestinal bleeding at Day 10 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">82, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 18</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to index PCI (femoral <break/>approach) at Day 1 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">58, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">ECMO and impella access-site bleeding due to first staged <break/>PCI at Day 13 (BARC3), intracranial bleeding at Day 15 <break/>(BARC3), and gastrointestinal bleeding at Day 26 (BARC5)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">89, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA at <break/>Day 22</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Unknown-site bleeding at Day 3 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">78, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>and distal <break/>LCX at Day 2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Pectoralis major bleeding due to chest compression at <break/>Day 0 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">79, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal-mid <break/>RCA at <break/>Day 10</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Unknown site bleeding at Day 1 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">11</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">86, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-distal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 10</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to first staged PCI <break/>(brachial approach) at Day 10 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">12</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LAD at <break/>Day 15</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to index PCI (femoral <break/>approach) at Day 2 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">88, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA <break/>and mid-LAD <break/>at Day 3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to index PCI (radial <break/>approach) at Day 0 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">14</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">UAP <break/>(class 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA and <break/>proximal LCX <break/>at Day 2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Cardiac tamponade and IABP access-site bleeding due <break/>to first staged PCI at Day 2 (BARC5)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">87, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">CCS</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>and proximal <break/>LCX at Day 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Unknown-site bleeding at Day 16 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">16</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">64, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LAD at <break/>Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI procedure-related bleeding due to index PCI at Day <break/>0 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">17</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 18</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI procedure-related bleeding due to index PCI at Day <break/>0 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">85, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LCX at <break/>Day 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to index PCI (femoral <break/>approach) at Day 1 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">84, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal RCA <break/>at Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to index PCI (radial <break/>approach) at Day 0 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">20</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">64, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Diagonal <break/>branch</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal RCA <break/>at Day 1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">PCI access-site bleeding due to first staged PCI (radial <break/>approach) at Day 1 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">21</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">62, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">CCS</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCX <break/>at Day 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Gastrointestinal bleeding at Day 9 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">22</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">73, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">CCS</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Gastrointestinal bleeding at Day 27 (BARC3)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">23</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">82, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">CCS</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid RCA at <break/>Day 7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td colspan="3" align="left" style="white-space:nowrap;" rowspan="1">Gastrointestinal bleeding at Day 3 (BARC3)</td></tr><tr><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>(B) </bold><break/><bold>No.</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Assigned </bold><break/><bold>group</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Age </bold><break/><bold>(years), </bold><break/><bold>sex</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Presentation</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Target </bold><break/><bold>lesion in the </bold><break/><bold>index PCI</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Target lesion </bold><break/><bold>in the first </bold><break/><bold>staged PCI</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Antiplatelet </bold><break/><bold>agents at </bold><break/><bold>the first </bold><break/><bold>staged PCI</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Target </bold><break/><bold>lesion in </bold><break/><bold>the second </bold><break/><bold>staged PCI</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Antiplatelet </bold><break/><bold>agents at </bold><break/><bold>the second </bold><break/><bold>staged PCI</bold></th><th align="center" style="white-space:nowrap;" rowspan="1" colspan="1"><bold>Details of the event</bold></th></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">1</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">71, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LAD at <break/>Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LCX at <break/>Day 21</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke at Day 28</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">69, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-distal LAD <break/>at Day 11</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Periprocedural MI due to <break/>first staged PCI at Day 11</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">65, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal RCA <break/>at Day 20</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST and spontaneous <break/>MI due to index PCI at Day 4</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">72, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCX <break/>at Day 8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Spontaneous MI (PCI for <break/>diagonal branch) at Day 4</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">81, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke with <break/>hemorrhagic conversion due <break/>to first staged PCI at Day 9</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">6</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">53, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 30</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST due to index <break/>PCI at Day 0</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">87, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCX <break/>at Day 7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Spontaneous MI (PCI for <break/>proximal RCA) at Day 11</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">8</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">58, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Periprocedural MI due to <break/>first staged PCI at Day 13 <break/>and cardiac death (cause <break/>of death: periprocedural MI <break/>due to first staged PCI) at 26</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">75, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Periprocedural MI due to <break/>first staged PCI at Day 10</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">10</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">75, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LCX at <break/>Day 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Spontaneous MI at Day 4 <break/>(PCI for diagonal branch <break/>due to spontaneous MI <break/>and scheduled staged PCI <break/>for mid-LCX on same day)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">11</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">88, F</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA <break/>and mid-LAD <break/>at Day 3</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Cardiac death (cause of <break/>death: myocardial <break/>infarction) at Day 12</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">12</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">UAP <break/>(class 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA and <break/>proximal LCX <break/>at Day 2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>monotherapy</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Cardiac death (cardiac <break/>tamponade due to first <break/>staged PCI) at Day 3</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">UAP <break/>(class 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal LCX <break/>at Day 29</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke due to first <break/>staged PCI at Day 7</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">14</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">No aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">76, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">UAP <break/>(class 3)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA and <break/>proximal-<break/>mid-LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA at <break/>Day 7</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-distal <break/>LAD at <break/>Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Periprocedural MI due to <break/>index PCI at Day 0</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">15</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">79, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">NSTEMI <break/>(Killip 4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-LCX</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 2</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Cardiac death (cause of <break/>death: myocardial <break/>infarction) at Day 3</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">16</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">53, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal LCX at <break/>Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST and <break/>periprocedural MI due to <break/>first staged PCI at Day 13</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">17</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">67, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>at Day 19</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid LCX at <break/>Day 21</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke at Day 1</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">18</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">55, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid- and <break/>distal RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LAD <break/>and distal <break/>LCX at Day 9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke at Day 10 <break/>(the association between <break/>staged PCI and ischemic <break/>stroke was unknown)</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">19</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">56, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCX <break/>at Day 11</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Spontaneous MI (PCI for <break/>proximal RCA) at Day 22</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">20</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">80, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 2)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCX <break/>at Day 6</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST and <break/>periprocedural MI due <break/>to index PCI at Day 0</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">21</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">91, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal and <break/>distal RCA at <break/>Day 13</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Ischemic stroke at Day 2</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">22</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">55, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">STEMI <break/>(Killip 4)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal <break/>LAD</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Distal LCX at <break/>Day 4</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST due to index <break/>PCI at Day 1</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">23</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">54, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">UAP <break/>(class 1)</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-distal <break/>RCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Proximal LCA <break/>at Day 9</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Definite ST and <break/>periprocedural MI due <break/>to index PCI at Day 0</td></tr><tr><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">24</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">DAPT</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">88, M</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">CCS</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">LMCA</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Mid-RCA at <break/>Day 5</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">Prasugrel <break/>and aspirin</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="center" style="white-space:nowrap;" rowspan="1" colspan="1">&#8211;</td><td align="left" style="white-space:nowrap;" rowspan="1" colspan="1">Periprocedural MI due to <break/>first staged PCI at Day 5</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CCS, chronic coronary syndrome; F, female; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LMCA, left main coronary artery; M, male; RCA, right coronary artery; UAP, unstable angina pectoris. Other abbreviations as in Tables 1,3.</p></fn></table-wrap-foot></table-wrap>
</p><p>The co-primary cardiovascular endpoint occurred in 14 (3.49%) patients in the no-aspirin group and 10 (2.42%) patients in the DAPT group at 1 month (HR 1.44; 95% CI 0.64&#8211;3.25; P=0.38; <xref rid="F2" ref-type="fig"><bold>Figure&#8197;2B</bold></xref>). The co-primary cardiovascular endpoint after the first staged PCI occurred in 10 (2.49%) patients in the no-aspirin group and 5 (1.21%) patients in the DAPT group (HR 2.07; 95% CI 0.71&#8211;6.05; <xref rid="T3" ref-type="table"><bold>Table&#8197;3</bold></xref>). The details of the co-primary cardiovascular endpoint are shown in <xref rid="T4" ref-type="table"><bold>Table&#8197;4B</bold></xref>. Among 14 patients who had a co-primary cardiovascular endpoint in the no-aspirin group, 7 patients (numbers 2, 5, 8, 9, 10, 12, and 13 in <xref rid="T4" ref-type="table"><bold>Table&#8197;4B</bold></xref>) were considered to have a procedural complication (e.g., periprocedural myocardial infarction, ischemic stroke, or cardiac death caused by cardiac tamponade) due to the staged PCI. Among 10 patients who had a co-primary cardiovascular endpoint in the DAPT group, 2 patients (numbers 16 and 24 in <xref rid="T4" ref-type="table"><bold>Table&#8197;4B</bold></xref>) were considered to have a procedural complication (e.g., definite stent thrombosis, or periprocedural myocardial infarction) due to the staged PCI.</p><p>Definite stent thrombosis occurred in 2 (0.50%) patients in the no-aspirin group and in 4 (0.97%) patients in the DAPT group (HR 0.51; 95% CI 0.09&#8211;2.81; <xref rid="T3" ref-type="table"><bold>Table&#8197;3</bold></xref>). Results for the other secondary endpoints are presented in <xref rid="T3" ref-type="table"><bold>Table&#8197;3</bold></xref>.</p><p>In the sensitivity analysis, after excluding patients who did not receive assigned antiplatelet agents at any staged PCI, the results were consistent with those in the main analysis (<xref rid="S1" ref-type="supplementary-material"><bold>Supplementary Table</bold></xref>).</p><p>In the subgroup analysis stratified by acute or non-acute coronary syndrome, the results were consistent with those in the main analysis (<xref rid="S1" ref-type="supplementary-material"><bold>Supplementary Figure&#8197;2</bold></xref>).</p></sec></sec><sec><title>Discussion</title><p>The main findings of the present STOPDAPT-3 subgroup analysis are as follows: (1) an aspirin-free prasugrel monotherapy relative to DAPT failed to reduce major bleeding within 1 month in patients undergoing staged PCI; and (2) an aspirin-free prasugrel monotherapy relative to DAPT had a numerically higher incidence of cardiovascular events within 1 month in patients undergoing staged PCI.</p><p>There are some clinical reasons to perform staged PCI, which include high-contrast medium exposure especially in patients with chronic kidney disease, high radiation exposure, complex lesions such as calcified lesions requiring atherectomy device or chronic total occlusion, unexpected lengthy procedure, and procedural complications or patient instability.<xref rid="B1" ref-type="bibr"><sup>1</sup></xref> Non-clinical reasons to perform staged PCI include the issues related to operator fatigue, logistics in the catheterization laboratory, and reimbursement (economic reasons).<xref rid="B1" ref-type="bibr"><sup>1</sup></xref> Previous randomized clinical trials have demonstrated the benefit of staged PCI for a non-culprit lesion compared with culprit-only PCI in patients with acute coronary syndrome.<xref rid="B14" ref-type="bibr"><sup>14</sup></xref><sup>&#8211;</sup><xref rid="B16" ref-type="bibr"><sup>16</sup></xref> In addition, several randomized clinical trials have suggested the benefit of immediate multivessel PCI compared with staged multivessel PCI in patients with acute coronary syndrome.<xref rid="B17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="B18" ref-type="bibr"><sup>18</sup></xref> In contrast, approximately 65&#8211;75% of patients with multivessel disease underwent staged PCI in real-world practice.<xref rid="B2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="B3" ref-type="bibr"><sup>3</sup></xref></p><p>P2Y<sub>12</sub>
inhibitor monotherapy after very short DAPT (1&#8211;3 months) compared with standard DAPT reduced major bleeding events without increasing cardiovascular events after PCI in several randomized clinical trials.<xref rid="B19" ref-type="bibr"><sup>19</sup></xref><sup>&#8211;</sup><xref rid="B23" ref-type="bibr"><sup>23</sup></xref> However, if patients required staged PCI procedures, they were enrolled after the completion of the final staged PCI procedures, and therefore, those who experienced bleeding or ischemic complications at the staged PCI were often not enrolled in these trials. Therefore, data of the optimal duration of DAPT in patients requiring staged PCI were scarce. In patients undergoing staged PCI in the GLOBAL LEADERS trial, which compared ticagrelor monotherapy after 1-month DAPT to the 12-month DAPT, the duration of DAPT was prolonged by the interval between the first index PCI and the staged PCI according to the study protocol.<xref rid="B4" ref-type="bibr"><sup>4</sup></xref> The subgroup analyses in patients undergoing staged PCI in the GLOBAL LEADERS trial showed that ticagrelor monotherapy after 1-month DAPT compared with the 12-month DAPT was associated with a lower incidence of major bleeding in patients with acute coronary syndrome, although the incidence of major bleeding was not significantly different between the 2 groups in the overall results of the GLOBAL LEADERS trial.<xref rid="B4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="B19" ref-type="bibr"><sup>19</sup></xref> Patients requiring staged PCI had a periprocedural bleeding risk due to multiple procedures, and an aspirin-free strategy for patients undergoing staged PCI during the periprocedural period might reduce bleeding events. However, an aspirin-free strategy compared with the DAPT strategy failed to reduce major bleeding within 1 month in patients undergoing staged PCI in the present study, which was consistent with the main results of STOPDAPT-3.<xref rid="B11" ref-type="bibr"><sup>11</sup></xref> The major component of bleeding in the present study was procedure-related bleeding, such as access-site bleeding. The removal of aspirin might be ineffective in reducing procedure-related bleeding.</p><p>Several single-arm studies reported that an aspirin-free strategy immediately after PCI was not associated with any spontaneous myocardial infarction or stent thrombosis in selected low-risk patients.<xref rid="B8" ref-type="bibr"><sup>8</sup></xref><sup>&#8211;</sup><xref rid="B10" ref-type="bibr"><sup>10</sup></xref> However, because patients requiring staged PCI were not enrolled in these studies, the safety of an aspirin-free strategy for patients undergoing staged PCI has not been evaluated so far. In the STOPDAPT-3 trial, patients undergoing staged PCI were recommended to take each assigned antiplatelet regimen without additional loading doses according to the study protocol, and more than 90% patients received the assigned antiplatelet regimen. The incidence of the co-primary cardiovascular endpoint was numerically higher in the no-aspirin group than in the DAPT group. In addition, the incidence of the co-primary cardiovascular endpoint, which occurred after the first staged PCI, was numerically higher in the no-aspirin group than in the DAPT group. Considering the similar risk of major bleeding between the no-aspirin and DAPT groups in patients undergoing staged PCI in the present study, DAPT should be continued up to at least 1 month after staged PCI.</p><sec><title>Study Limitations</title><p>The original STOPDAPT-3 trial had limitations such as an open-label design, use of reduced doses of prasugrel that were only approved in Japan, enrollment of only Japanese patients who might have a different risk&#8211;benefit balance for bleeding and cardiovascular events compared with other races, and no stringent recommendations on antithrombotic therapy before randomization.<xref rid="B11" ref-type="bibr"><sup>11</sup></xref> Reduced doses of prasugrel (at loading/maintenance of 20/3.75 mg), which were only approved in Japan, could be a problem when extrapolating the present study results outside of Japan. Nevertheless, in the pivotal study of prasugrel in Japan, the magnitude of risk reduction for cardiovascular events with 20/3.75 mg of prasugrel compared with 300/75 mg of clopidogrel was similar to that in the global pivotal trial using 60/10 mg of prasugrel.<xref rid="B24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="B25" ref-type="bibr"><sup>25</sup></xref> The open-label trial design might have influenced the treatment after assignment. Indeed, the prescription rate of proton-pump inhibitors was higher in the DAPT group than in the no-aspirin group, which might affect the lack of large difference in the co-primary bleeding endpoint. There are other important limitations in this study. First, the primary hypothesis in the original STOPDAPT-3 trial was not met. Moreover, the present subgroup analysis was post hoc and underpowered. Therefore, the present study should be interpreted as exploratory and hypothesis generating, and no statistically significant difference in the co-primary endpoints in the present study would preclude any strong clinical conclusions. The wide CIs of HRs of outcomes should necessitate further investigation of this topic. Second, the present study did not include patients who underwent staged PCI beyond 1 month. The study protocol recommended staged PCI within 3 months after randomization. The actual execution and timing of staged PCI were left to the discretion of each attending physician. Therefore, the allocated group (no-aspirin or DAPT) might affect the execution and timing of staged PCI. However, the number of patients who underwent staged PCI within 1 month was not different between the no-aspirin and DAPT groups. Third, the present study could not consider patients in whom staged PCI was planned, but not performed, due to unexpected clinical events. Last, we did not collect data on the reasons why the operator decided to perform the staged PCI.</p></sec></sec><sec><title>Conclusions</title><p>An aspirin-free prasugrel monotherapy relative to DAPT had numerically higher risks of cardiovascular and major bleeding events in patients undergoing staged PCI at 1 month. The findings of the present study should be considered as hypothesis generating because of the post hoc and underpowered subgroup analyses of the overall STOPDAPT-3 trial, which was negative for the co-primary bleeding endpoint. Further investigations of an aspirin-free prasugrel monotherapy relative to DAPT should be mandatory for these patients.</p></sec><sec><title>Sources of Funding</title><p>Abbott Medical Japan.</p></sec><sec><title>Disclosures</title><p>K.Y. reports honoraria from Abbott Medical Japan. M.N. reports honoraria from Abbott Medical Japan, Daiichi Sankyo, Medtronic, Terumo, Japan Lifeline, Asahi Intecc, Bristol-Myers Squibb, Otsuka, Amgen, Sanofi, Takeda and Bayer. H.W. reports personal fees from Abbott Medical Japan during the conduct of the study, as well as personal fees from Daiichi Sankyo, Kowa, Abiomed, Bayer, Pfizer, Bristol-Myers Squibb, and Otsuka outside of the submitted work. T.M. reports lecturer&#8217;s fees from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Pfizer, Tsumura and UCB, a manuscript fee from Pfizer, and being on the advisory board for GlaxoSmithKline, Novartis and Teijin. Y.O. reports honoraria from Abbott Medical Japan. S.S. reports personal fees from Abbott Medical Japan and Daiichi Sankyo outside of the submitted work. K.K. reports honorarium for lecture from Boston Scientific, Abbott Medical, Medtronic, Otsuka, Daiichi-Sankyo, Amgen, Novartis, Behringer, Bayer, Life Science Institute, Mochida, and Novo Nordisk, and a scholarship fund from Abbott Medical. Ta. Kimura reports grants from Abbott Medical Japan and Boston Scientific, and being an advisory board member of Abbott Medical Japan and Terumo Japan. K.O. is a member of <italic toggle="yes">Circulation Reports</italic>&#8217; Editorial Team. No other disclosures are reported.</p></sec><sec><title>IRB Information</title><p>The present study was approved by the Kyoto University Certified Review Board and Ethics Committee (Reference no. CRB5180002).</p></sec><sec sec-type="supplementary-material"><title>Supplementary Files</title><supplementary-material id="S1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary File 1</label><caption><p>Table of Contents.
Supplementary Table
Supplementary Figure 1.
Supplementary Figure 2.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="circrep-7-451-s001.pdf" id="d67e3661" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We appreciate the study investigators for their efforts in enrolling patients and collecting data. We also appreciate the members of the Research Institute for Production Development for coordinating the study.</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The deidentified participant data will not be shared.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Spitzer E, McFadden E, Vranckx P, de Vries T, Ren B, Collet C, et al.</person-group><article-title>Defining staged procedures for percutaneous coronary intervention trials</article-title>: A guidance document. <source><italic toggle="yes">JACC Cardiovasc Interv</italic></source><year>2018</year>; <volume>11</volume>: <fpage>823</fpage>&#8211;<lpage>832</lpage>.<pub-id pub-id-type="pmid">29747912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcin.2018.03.044</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Toyota T, Morimoto T, Shiomi H, Yamaji K, Ando K, Ono K, et al.</person-group><article-title>Single-session versus staged procedures for elective multivessel percutaneous coronary intervention.</article-title><source><italic toggle="yes">Heart</italic></source><year>2018</year>; <volume>104</volume>: <fpage>936</fpage>&#8211;<lpage>944</lpage>.<pub-id pub-id-type="pmid">29146627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/heartjnl-2017-312117</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Yamamoto K, Shiomi H, Morimoto T, Miyazawa A, Watanabe H, Nakamura S, et al.</person-group><article-title>Single-session versus staged multivessel optimal IVUS-guided PCI in patients with CCS or NSTE-ACS.</article-title><source><italic toggle="yes">JACC Asia</italic></source><year>2023</year>; <volume>3</volume>: <fpage>649</fpage>&#8211;<lpage>661</lpage>.<pub-id pub-id-type="pmid">37614540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacasi.2023.03.013</pub-id><pub-id pub-id-type="pmcid">PMC10442883</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Kawashima H, Tomaniak M, Ono M, Wang R, Hara H, Gao C, et al.</person-group><article-title>Safety and efficacy of 1-month dual antiplatelet therapy (ticagrelor+aspirin) followed by 23-month ticagrelor monotherapy in patients undergoing staged percutaneous coronary intervention (a sub-study from GLOBAL LEADERS).</article-title><source><italic toggle="yes">Am J Cardiol</italic></source><year>2021</year>; <volume>138</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">33065080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2020.09.057</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al.</person-group><article-title>2023 ESC guidelines for the management of acute coronary syndromes.</article-title><source><italic toggle="yes">Eur Heart J</italic></source><year>2023</year>; <volume>44</volume>: <fpage>3720</fpage>&#8211;<lpage>3826</lpage>.<pub-id pub-id-type="pmid">37622654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad191</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al.</person-group><article-title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease</article-title>: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <source><italic toggle="yes">Circulation</italic></source><year>2023</year>; <volume>148</volume>: <fpage>e9</fpage>&#8211;<lpage>e119</lpage>.<pub-id pub-id-type="pmid">37471501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000001168</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al.</person-group><article-title>JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease.</article-title><source><italic toggle="yes">Circ J</italic></source><year>2020</year>; <volume>84</volume>: <fpage>831</fpage>&#8211;<lpage>865</lpage>.<pub-id pub-id-type="pmid">32173684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.CJ-19-1109</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Kogame N, Guimar&#227;es PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, et al.</person-group><article-title>Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD</article-title>: The ASET pilot study. <source><italic toggle="yes">JACC Cardiovasc Interv</italic></source><year>2020</year>; <volume>13</volume>: <fpage>2251</fpage>&#8211;<lpage>2262</lpage>.<pub-id pub-id-type="pmid">32950419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcin.2020.06.023</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Muramatsu T, Masuda S, Kotoku N, Kozuma K, Kawashima H, Ishibashi Y, et al.</person-group><article-title>Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for japanese patients with chronic coronary syndrome (ASET-JAPAN).</article-title><source><italic toggle="yes">Circ J</italic></source><year>2023</year>; <volume>87</volume>: <fpage>857</fpage>&#8211;<lpage>865</lpage>.<pub-id pub-id-type="pmid">36908118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.CJ-23-0051</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">van der Sangen NMR, Claessen BEPM, K&#252;&#231;&#252;k IT, den Hartog AW, Baan J, Beijk MAM, et al.</person-group><article-title>Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients</article-title>: The OPTICA study. <source><italic toggle="yes">EuroIntervention</italic></source><year>2023</year>; <volume>19</volume>: <fpage>63</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">36734020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4244/EIJ-D-22-00886</pub-id><pub-id pub-id-type="pmcid">PMC10173755</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al.</person-group><article-title>An aspirin-free versus dual antiplatelet strategy for coronary stenting</article-title>: STOPDAPT-3 randomized trial. <source><italic toggle="yes">Circulation</italic></source><year>2024</year>; <volume>149</volume>: <fpage>585</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="pmid">37994553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.123.066720</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al.</person-group><article-title>Standardized bleeding definitions for cardiovascular clinical trials</article-title>: A consensus report from the Bleeding Academic Research Consortium. <source><italic toggle="yes">Circulation</italic></source><year>2011</year>; <volume>123</volume>: <fpage>2736</fpage>&#8211;<lpage>2747</lpage>.<pub-id pub-id-type="pmid">21670242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.110.009449</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al.</person-group><article-title>Clinical end points in coronary stent trials</article-title>: A case for standardized definitions. <source><italic toggle="yes">Circulation</italic></source><year>2007</year>; <volume>115</volume>: <fpage>2344</fpage>&#8211;<lpage>2351</lpage>.<pub-id pub-id-type="pmid">17470709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.106.685313</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, et al.</person-group><article-title>Fractional Flow reserve-guided multivessel angioplasty in myocardial infarction.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2017</year>; <volume>376</volume>: <fpage>1234</fpage>&#8211;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">28317428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1701067</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, et al.</person-group><article-title>Complete revascularization with multivessel PCI for myocardial infarction.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2019</year>; <volume>381</volume>: <fpage>1411</fpage>&#8211;<lpage>1421</lpage>.<pub-id pub-id-type="pmid">31475795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1907775</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, et al.</person-group><article-title>Complete or culprit-only PCI in older patients with myocardial infarction.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2023</year>; <volume>389</volume>: <fpage>889</fpage>&#8211;<lpage>898</lpage>.<pub-id pub-id-type="pmid">37634150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2300468</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabat&#233; M, et al.</person-group><article-title>Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC)</article-title>: A prospective, open-label, non-inferiority, randomised trial. <source><italic toggle="yes">Lancet</italic></source><year>2023</year>; <volume>401</volume>: <fpage>1172</fpage>&#8211;<lpage>1182</lpage>.<pub-id pub-id-type="pmid">36889333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)00351-3</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">St&#228;hli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al.</person-group><article-title>Timing of complete revascularization with multivessel PCI for myocardial infarction.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2023</year>; <volume>389</volume>: <fpage>1368</fpage>&#8211;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">37634190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2307823</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, et al.</person-group><article-title>Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent</article-title>: A multicentre, open-label, randomised superiority trial. <source><italic toggle="yes">Lancet</italic></source><year>2018</year>; <volume>392</volume>: <fpage>940</fpage>&#8211;<lpage>949</lpage>.<pub-id pub-id-type="pmid">30166073</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)31858-0</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al.</person-group><article-title>Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI</article-title>: The STOPDAPT-2 randomized clinical trial. <source><italic toggle="yes">JAMA</italic></source><year>2019</year>; <volume>321</volume>: <fpage>2414</fpage>&#8211;<lpage>2427</lpage>.<pub-id pub-id-type="pmid">31237644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.8145</pub-id><pub-id pub-id-type="pmcid">PMC6593641</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Hahn JY, Bin Song Y, Oh JH, Chun WJ, Park YH, Jang WJ, et al.</person-group><article-title>Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention</article-title>: The SMART-CHOICE randomized clinical trial. <source><italic toggle="yes">JAMA</italic></source><year>2019</year>; <volume>321</volume>: <fpage>2428</fpage>&#8211;<lpage>2437</lpage>.<pub-id pub-id-type="pmid">31237645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.8146</pub-id><pub-id pub-id-type="pmcid">PMC6593635</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al.</person-group><article-title>Ticagrelor with or without aspirin in high-risk patients after PCI.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2019</year>; <volume>381</volume>: <fpage>2032</fpage>&#8211;<lpage>2042</lpage>.<pub-id pub-id-type="pmid">31556978</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1908419</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al.</person-group><article-title>Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome</article-title>: The TICO randomized clinical trial. <source><italic toggle="yes">JAMA</italic></source><year>2020</year>; <volume>323</volume>: <fpage>2407</fpage>&#8211;<lpage>2416</lpage>.<pub-id pub-id-type="pmid">32543684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.7580</pub-id><pub-id pub-id-type="pmcid">PMC7298605</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al.</person-group><article-title>Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome</article-title>: The PRASFIT-ACS study. <source><italic toggle="yes">Circ J</italic></source><year>2014</year>; <volume>78</volume>: <fpage>1684</fpage>&#8211;<lpage>1692</lpage>.<pub-id pub-id-type="pmid">24759796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-13-1482</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.</person-group><article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes.</article-title><source><italic toggle="yes">N Engl J Med</italic></source><year>2007</year>; <volume>357</volume>: <fpage>2001</fpage>&#8211;<lpage>2015</lpage>.<pub-id pub-id-type="pmid">17982182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0706482</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>